The PAHO Strategic Fund has supported the Brazilian government since 2001 in purchasing quality-assured medicines and supplies for malaria, leishmaniasis, tuberculosis, HIV and Chagas disease programs, as well as anthelmintics and insecticides.
In 2021, given the challenging context of the COVID-19 pandemic and the shortage of medications for orotracheal intubation in the Brazilian market, the Strategic Fund also supported the Ministry of Health (MoH) in purchasing these medications.
To better support Brazil during this emergency, a Task Force was coordinated by the PAHO Office in Brazil, with the participation of the MoH and Anvisa, to quickly guarantee and comply with the technical, regulatory, and administrative requirements, and to ensure the supply of medicines to fight the disease. The creation of this working group facilitated the communication between the three entities to participate in procurement processes, eliminating bottlenecks and promoting access to medicines to meet the population’s needs During this period, approximately 23 million units of 17 orotracheal intubation medicines were procured, totaling an investment of US$ 76 million, which were distributed to all the states in partnership with the National Council of Health Secretaries (CONASS) and the National Council of Municipal Health Secretariats (CONASEMS). Regarding the medicines acquired by the Strategic Fund, in 2021, 110.5 million units of medications and insecticides, totaling US$ 64 million, were delivered to treat leishmaniasis, tuberculosis, HIV, Chagas disease, and helminths. These medicines and health supplies were not previously registered or marketed in Brazilian territory.
The technical and administrative work of the PAHO Office in Brazil, together with colleagues based at headquarters in Washington, D.C., as well as the partnership established with the MoH and Anvisa, were of great importance in reaching the results presented.
*Source: Strategic Fund Annual Report 2021: Prioritizing Access to Medicines and Supplies for Health Security and Universal Health PAHO/HSS/SF/22-0020